Biomarin Pharmaceutical (NASDAQ:BMRN) is preparing to release its quarterly earnings on Tuesday, 2024-10-29. Here's a brief overview of what investors should keep in mind before the announcement.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by ...

JPMorgan analyst Jessica Fye lowered the firm’s price target on BioMarin (BMRN) to $109 from $110 and keeps an Overweight rating on the shares post the Q3 report. The firm sees an attractive ...

BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.46 per share a year ago.

BioMarin Pharmaceutical BMRN reported adjusted earnings per share of 91 cents in third-quarter 2024, beating the Zacks Consensus Estimate of 78 cents. Quarterly earnings rose 98% year over year ...

Biomarin Pharmaceutical Inc. earnings at a glance ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...

Fintel reports that on October 30, 2024, William Blair downgraded their outlook for BioMarin Pharmaceutical (WBAG:BMRN) from Outperform to Market Perform. There are 1,150 funds or institutions ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 5,590,000 shares ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report)’s stock price reached a new 52-week low during trading on Wednesday following a weaker than expected earnings announcement. The stock ...

Blue Trust Inc. raised its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 504.9% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 859 shares ...

BioMarin is a biotechnology company “dedicated to transforming lives through genetic discovery.” The company develops and commercializes targeted therapies that address the root cause of ...